Studies evaluating FCR alone and in combination with other agents in refractory/relapsed CLL. NR indicates not reported; F, fludarabine; C, cyclophosphamide; R, rituximab; L, lumiliximab; A, alemtuzumab; M, mitoxantrone; and m, months. *CR + CR unconfirmed.